Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR17866847

—

0069c0a0-f82f-5576-b283-9e0262a6a220

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
age_years
39.8

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • APICAL_SURFACE+0.460
  • HEDGEHOG_SIGNALING+0.420
  • MYOGENESIS+0.370
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
  • APICAL_JUNCTION+0.340
  • KRAS_SIGNALING_DN+0.330
  • ALLOGRAFT_REJECTION+0.270
  • INFLAMMATORY_RESPONSE+0.270
  • ANGIOGENESIS+0.260
  • COAGULATION+0.260

Top 10 suppressed

  • MYC_TARGETS_V1-0.690
  • E2F_TARGETS-0.630
  • MYC_TARGETS_V2-0.600
  • OXIDATIVE_PHOSPHORYLATION-0.550
  • G2M_CHECKPOINT-0.490
  • MTORC1_SIGNALING-0.480
  • PROTEIN_SECRETION-0.460
  • UNFOLDED_PROTEIN_RESPONSE-0.450
  • DNA_REPAIR-0.440
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-50-8459-01A-11R-2326-07
lung-landscapes@6
—cohortMD20.956
2a802b49c.736d.427c.bcca.8375c4171284
lung-landscapes@6
—cohortA10.929
3TCGA-99-AA5R-01A-11R-A39D-07
lung-landscapes@6
—cohortA10.926
4TCGA-E2-A1IJ-01A-11R-A144-07
breast-umap@18
—A0.926
5TCGA-55-8619-01A-11R-2403-07
lung-landscapes@6
—cohortA10.918
6TCGA-98-A53H-01A-12R-A262-07
lung-landscapes@6
—cohortA10.917
7SRR1498861
brain-umap@2
GTEX—0.916
82cec663c-00c8-48b5-967b-f2a53c0fb409
colon-landscapes@1
——0.916
959f108c6-677f-4cf2-89fd-6bd15133dd6f
colon-landscapes@1
——0.915
10TCGA-AR-A2LN-01A-21R-A18M-07
breast-umap@18
—A0.915

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 28 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
APICAL_SURFACE0.460Temsirolimus— uncovered
HEDGEHOG_SIGNALING0.420Inavolisib— uncovered
MYOGENESIS0.370Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.350Inavolisib— uncovered
APICAL_JUNCTION0.340Inavolisib— uncovered
KRAS_SIGNALING_DN0.330Remibrutinib— uncovered
ALLOGRAFT_REJECTION0.270Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.270Idelalisib— uncovered
ANGIOGENESIS0.260Remibrutinib— uncovered
COAGULATION0.260Binimetinib— uncovered
UV_RESPONSE_DN0.260Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.250Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.220Idelalisib— uncovered
HYPOXIA0.210Idelalisib— uncovered
COMPLEMENT0.200Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.200Inavolisib— uncovered
TGF_BETA_SIGNALING0.200Inavolisib— uncovered
NOTCH_SIGNALING0.190Inavolisib— uncovered
IL2_STAT5_SIGNALING0.180Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.180Inavolisib— uncovered